APSR2026-1006

 
Late-Breaking
Submitted
Oral Presentation
AO10-006
 
 
https://storage.unitedwebnetwork.com/files/1285/1204469-46903-Song APSR 2026 Slides FINAL_432521.pptx
Format: PPTX Only
 
Format: PDF Only
16. Interstitial Lung Disease
15

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Jin Woo Song * University of Ulsan College of Medicine, Asan Medical Center Department of Pulmonary and Critical Care Medicine Seoul Republic of Korea
Yoshikazu Inoue - NHO Kinki Chuo Chest Medical Center Clinical Research Center Osaka Japan Osaka Anti-tuberculosis Association Osaka Fukujuji Hospital Internal Medicine Osaka Japan
Keiichi Akasaka - Saitama Red Cross Hospital Department of Respiratory Mediine Saitama Japan
Toru Arai - NHO Kinki Chuo Chest Medical Center Clinical Research Center Osaka Japan
Tomohisa Baba - Kanagawa Cardiovascular and Respiratory Center Department of Respiratory Medicine Kanagawa Japan
Satoru Ito - Aichi Medical University Hospital Department of Respiratory Medicine and Allergology Aichi Japan
Tadahisa Numakura - Tohoku University Graduate School of Medicine Department of Respiratory Medicine Sendai Japan
Shinya Ohkouchi - Tohoku University Graduate School of Medicine Department of Respiratory Medicine Sendai Japan
Jimyung Park - Seoul National University Hospital Pulmonary and Critical Care Medicine Seoul Republic of Korea
Moo Suk Park - Severance Hospital - Yonsei University Health System Pulmonary and Critical Care Medicine Seoul Republic of Korea
Takuji Suzuki - Chiba University Hospital Department of Respiratory Mediine Chiba Japan
Takayuki Takimoto - NHO Kinki Chuo Chest Medical Center Clinical Research Center Osaka Japan
Etsuro Yamaguchi - Aichi Medical University Hospital Department of Respiratory Medicine Aichi Japan
Yasmine Wasfi - Savara Inc. Clinical Development Langhorne, PA United States
Brian Robinson - Savara Inc. Global Medical Affairs Langhorne, PA United States
Presenting Author Details
Jin Woo
Song
jwsongasan@gmail.com
+82230103993
51-60
 
Original Research
The efficacy of inhaled molgramostim in Japanese and South Korean patients with autoimmune pulmonary alveolar proteinosis (aPAP): Results from the IMPALA-2 Phase 3 clinical trial
Maximum 25 words
Abstract Content
aPAP, a rare lung disease caused by autoantibodies to granulocyte-macrophage colony-stimulating factor (GM-CSF), is characterized by alveolar surfactant accumulation and impaired oxygen delivery to blood. Molgramostim inhalation solution (molgramostim) is a recombinant human GM-CSF being evaluated for the treatment of aPAP patients in a Phase 3 clinical trial (IMPALA-2). IMPALA-2 met its primary endpoint in the overall patient population recruited from 43 clinical sites in 16 countries. Here, we report the effects of molgramostim in Japanese and South Korean aPAP patients from IMPALA-2.
IMPALA-2 is a global, randomized, double-blind, placebo-controlled trial of inhaled molgramostim in adult aPAP patients receiving nebulized molgramostim 300 µg or placebo once daily for 48 weeks. The primary endpoint was change from baseline in percent predicted diffusing capacity of the lungs for carbon monoxide adjusted for hemoglobin (DLCO%) at Week 24. Secondary endpoints included changes from baseline in DLCO% at Week 48, and St. George’s Respiratory Questionnaire (SGRQ) Total and Activity scores and exercise capacity (expressed as peak metabolic equivalents) at Weeks 24 and 48.
A total of 69 patients from Japan and South Korea were enrolled; 35 were randomized to receive molgramostim and 34 to receive placebo. A numerical improvement in DLCO% was observed with molgramostim compared with placebo at Week 24 (difference in least squares mean [LSM] change 4.8%; 95% CI -0.6, 10.2). Molgramostim patients also had greater mean improvements in DLCO% at Week 48 (7.0%; 95% CI 0.6, 13.4), and SGRQ Total score at Week 24 (-6.7; 95% CI -12.9, -0.5) and at Week 48 (-6.8; 95% CI -14.3, 0.8) than placebo patients. Other secondary endpoints favored molgramostim. Molgramostim was well-tolerated; no treatment-related adverse events led to discontinuation of molgramostim.
Molgramostim improved pulmonary gas exchange and respiratory HRQoL in the Japanese-South Korean subgroup of aPAP patients.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
autoimmune pulmonary alveolar proteinosis (aPAP), recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF)
maximum 3 keywords and no abbreviations, separated by commas
Funded by Savara Inc. Clinicaltrial.gov: NCT04544293
305